Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Health and Healthcare

Published: September 12, 2018 9:55 am

Last Updated: January 11, 2020 6:04 pm

Gilead Sciences Inc. (NASDAQ: GILD) shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with Precision BioSciences to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.

Under the terms of the collaboration agreement, Precision will be primarily responsible for the development, formulation and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies.

Also, Gilead will fully fund the research and development. Precision is eligible to receive milestone payments of up to an aggregate of $445 million and tiered royalties that go up to the mid-teens for commercial products developed through the collaboration.

John McHutchison, MD, chief scientific officer and head of Research and Development at Gilead, commented:

Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic hepatitis B virus infection. We are excited about the potential of genome editing and Precision’s ARCUS technology, which has demonstrated promising in vitro activity. We look forward to exploring this technology as an important component of our HBV cure research efforts.

Separately, Gilead announced results from its rheumatoid arthritis trial. The company said that its drug filgotinib was generally well-tolerated in the FINCH 2 trial, with no new safety signals compared to those reported in previous trials of filgotinib.

Also, the Phase 3 study of filgotinib achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20% response (ACR20) at Week 12. Also at Weeks 12 and 24, the proportion of patients achieving ACR50 and ACR70, low disease activity and clinical remission were significantly higher for patients receiving once-daily filgotinib 100 mg or 200 mg compared to patients receiving placebo.

Shares of Gilead were last seen up about 4% at $75.13 on Wednesday, with a consensus analyst price target of $87.87 and a 52-week range of $64.27 to $89.54.

24/7 Wall St.
Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.